News

Mon, 14/08/2017
Renowned AIDS researcher presents his work
Mainz. HIV-1, the major causative agent of AIDS, has infected more than 60 million people and caused around 20 million deaths worldwide (WHO report 2009). Prof. Frank Kirchhoff, director of the Institute of Molecular Virology, Ulm, is one of Germany’s most recognized scientists investigating HIV-1. Kirchoff has been honoured by numerous awards – among them […]...more
Thu, 06/07/2017
From bistability to complexity in the cortical network
Mainz. SFB-PI Albrecht Stroh is proud to welcome Prof. María Sanches Vives from the Institut d’Investigacions Biomediques in Barcelona as a guest lecturer within the FTN seminar series 2017. Prof. Sanches Vives is ICREA Research Professor at the IDIBAPS (Institut d’Investigacions Biomediques August Pi i Sunyer) in Barcelona since 2008, where she is the head […]...more
Thu, 22/06/2017
CSF diagnostics in neurodegenerative diseases
Munich. Prof. Markus Otto from the Department of Neurology Ulm is invited speaker at the neurocolloquium Munich. Prof. Otto is head of the scientific working group on neurochemistry and neurodegeneration at Ulm University and expert on neurochemical diagnosis of neurodegenerative disease (14-3-3, Tau-protein, Abeta-Peptides, S-100B, H-FABP, alpha synuclein) as well as head of a sample […]...more


Wed, 17/05/2017 | Swedish data on Rituximab – presentation by Fredrik Piehl

Munich. Sweden is the only country where the MS treatment Rituximab is frequently used even if it has not been formally approved. The neuroimmunologist mainly responsible for this fact is MS researcher Fredrik Piehl from Karolinska Institutet in Stockholm/Sweden. His research group provided observational data on Rituximab therapy and will now start a large clinical follow-up trial on this and other MS therapies. He will present his research at the Neurological Colloquium:

When?: Wednesday, May 31, 6:00-7:30 PM

Where?: Library, 4th floor, Neuro-Kopf-Zentrum, Klinikum rechts der Isar, Ismaninger Str. 22, Munich